Financhill
Sell
28

CTXR Quote, Financials, Valuation and Earnings

Last price:
$0.70
Seasonality move :
-15.73%
Day range:
$0.68 - $0.74
52-week range:
$0.65 - $26.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.12x
Volume:
157.3K
Avg. volume:
145K
1-year change:
-95.69%
Market cap:
$7.3M
Revenue:
--
EPS (TTM):
-$5.79

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CTXR
Citius Pharmaceuticals
-- $0.11 -- -75.33% $9.00
ATNM
Actinium Pharmaceuticals
-- -$0.28 -100% -7.24% $5.00
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$1.56 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CTXR
Citius Pharmaceuticals
$0.71 $9.00 $7.3M -- $0.00 0% --
ATNM
Actinium Pharmaceuticals
$1.65 $5.00 $51.5M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.57 $0.85 $3.3M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.71 -- $27.5M -- $0.00 0% --
OGEN
Oragenics
$0.19 $1.00 $4.1M -- $0.00 0% 1.84x
TOVX
Theriva Biologics
$0.43 $7.00 $3.5M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CTXR
Citius Pharmaceuticals
-- -2.327 -- --
ATNM
Actinium Pharmaceuticals
-- -3.541 -- 9.03x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
NNVC
Nanoviricides
-- 2.080 -- --
OGEN
Oragenics
-- 3.254 -- --
TOVX
Theriva Biologics
-- -2.512 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CTXR
Citius Pharmaceuticals
-- -$11.3M -- -- -- -$4.5M
ATNM
Actinium Pharmaceuticals
-- -$16.6M -95.08% -95.08% -12769.14% -$7.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Citius Pharmaceuticals vs. Competitors

  • Which has Higher Returns CTXR or ATNM?

    Actinium Pharmaceuticals has a net margin of -- compared to Citius Pharmaceuticals's net margin of -11511.11%. Citius Pharmaceuticals's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    CTXR
    Citius Pharmaceuticals
    -- -$1.27 --
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
  • What do Analysts Say About CTXR or ATNM?

    Citius Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 1165.65%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 203.03%. Given that Citius Pharmaceuticals has higher upside potential than Actinium Pharmaceuticals, analysts believe Citius Pharmaceuticals is more attractive than Actinium Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTXR
    Citius Pharmaceuticals
    1 1 0
    ATNM
    Actinium Pharmaceuticals
    2 1 0
  • Is CTXR or ATNM More Risky?

    Citius Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.748% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.236, suggesting its less volatile than the S&P 500 by 123.637%.

  • Which is a Better Dividend Stock CTXR or ATNM?

    Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTXR or ATNM?

    Citius Pharmaceuticals quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. Citius Pharmaceuticals's net income of -$10.9M is higher than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTXR
    Citius Pharmaceuticals
    -- -- -- -$10.9M
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
  • Which has Higher Returns CTXR or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Citius Pharmaceuticals's net margin of -49.65%. Citius Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    CTXR
    Citius Pharmaceuticals
    -- -$1.27 --
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About CTXR or NBY?

    Citius Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 1165.65%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.23%. Given that Citius Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Citius Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTXR
    Citius Pharmaceuticals
    1 1 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is CTXR or NBY More Risky?

    Citius Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.748% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock CTXR or NBY?

    Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTXR or NBY?

    Citius Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Citius Pharmaceuticals's net income of -$10.9M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTXR
    Citius Pharmaceuticals
    -- -- -- -$10.9M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns CTXR or NNVC?

    Nanoviricides has a net margin of -- compared to Citius Pharmaceuticals's net margin of --. Citius Pharmaceuticals's return on equity of -- beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CTXR
    Citius Pharmaceuticals
    -- -$1.27 --
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About CTXR or NNVC?

    Citius Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 1165.65%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 280.12%. Given that Citius Pharmaceuticals has higher upside potential than Nanoviricides, analysts believe Citius Pharmaceuticals is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTXR
    Citius Pharmaceuticals
    1 1 0
    NNVC
    Nanoviricides
    0 0 0
  • Is CTXR or NNVC More Risky?

    Citius Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.748% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

  • Which is a Better Dividend Stock CTXR or NNVC?

    Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTXR or NNVC?

    Citius Pharmaceuticals quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Citius Pharmaceuticals's net income of -$10.9M is lower than Nanoviricides's net income of -$2.2M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTXR
    Citius Pharmaceuticals
    -- -- -- -$10.9M
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns CTXR or OGEN?

    Oragenics has a net margin of -- compared to Citius Pharmaceuticals's net margin of --. Citius Pharmaceuticals's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CTXR
    Citius Pharmaceuticals
    -- -$1.27 --
    OGEN
    Oragenics
    -- -$0.12 --
  • What do Analysts Say About CTXR or OGEN?

    Citius Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 1165.65%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 420.83%. Given that Citius Pharmaceuticals has higher upside potential than Oragenics, analysts believe Citius Pharmaceuticals is more attractive than Oragenics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTXR
    Citius Pharmaceuticals
    1 1 0
    OGEN
    Oragenics
    0 1 0
  • Is CTXR or OGEN More Risky?

    Citius Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.748% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

  • Which is a Better Dividend Stock CTXR or OGEN?

    Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTXR or OGEN?

    Citius Pharmaceuticals quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Citius Pharmaceuticals's net income of -$10.9M is lower than Oragenics's net income of -$2.2M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus 1.84x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTXR
    Citius Pharmaceuticals
    -- -- -- -$10.9M
    OGEN
    Oragenics
    1.84x -- -- -$2.2M
  • Which has Higher Returns CTXR or TOVX?

    Theriva Biologics has a net margin of -- compared to Citius Pharmaceuticals's net margin of --. Citius Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CTXR
    Citius Pharmaceuticals
    -- -$1.27 --
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About CTXR or TOVX?

    Citius Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 1165.65%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1527.91%. Given that Theriva Biologics has higher upside potential than Citius Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Citius Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTXR
    Citius Pharmaceuticals
    1 1 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is CTXR or TOVX More Risky?

    Citius Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.748% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

  • Which is a Better Dividend Stock CTXR or TOVX?

    Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTXR or TOVX?

    Citius Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Citius Pharmaceuticals's net income of -$10.9M is lower than Theriva Biologics's net income of -$4.3M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTXR
    Citius Pharmaceuticals
    -- -- -- -$10.9M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Tesla Stock Overvalued or a Buy for the Next Decade?
Is Tesla Stock Overvalued or a Buy for the Next Decade?

Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…

Is Apple Stock Undervalued or Overvalued?
Is Apple Stock Undervalued or Overvalued?

For many years, Apple (NASDAQ:AAPL) was just about the perfect…

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
58
TNXP alert for May 28

Tonix Pharmaceuticals Holding [TNXP] is up 1.57% over the past day.

Sell
37
ATS alert for May 28

ATS [ATS] is down 1.27% over the past day.

Buy
88
SMR alert for May 28

NuScale Power [SMR] is down 0.37% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock